A study testing whether a GLP-1 medicine, semaglutide, can help people protect their kidneys.

Recruiting now. Registry record last updated July 27, 2026.

Who can join: Adults 20+, have chronic kidney disease.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 5.3 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor Srinvasan BeddhuDrug semaglutideClass GLP-1 RASites 2 USEnrollment target 156

What this study is for

Primary condition: Chronic Kidney Diseases. Also studied in: Obesity.

Full scientific study title: Sit Less, Interact and Move More (SLIMM) 2 Study.

Who can join

Age20 and upSexAny

Adults 20+, have chronic kidney disease. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
Able to perform resistance training
Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop

Key exclusion criteria

Type 1 Diabetes
History of gastroparesis or paralytic ileus
At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
Previous bariatric surgery

Where this trial is enrolling

This trial has 2 sites across 2 states. Contact a site coordinator directly to start screening.

Find a site near you

California1 site

Stanford University
Stanford, California
Edison Lee650-497-7526elee125@stanford.edu

Utah1 site

University of Utah
Salt Lake City, Utah
Judy Carle801-585-1113jcarle@hsc.utah.edu

Follow this trial

We email you if NCT05173714 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: December 1, 2021. Expected completion: March 31, 2027. Last updated on ClinicalTrials.gov: July 27, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.